Advertisement

ASTRO 2015: Coordinated Radiation Therapy and Palliative Care Based on Patient Feedback Lead to Better Quality of Life, Reduced Health-Care Costs

Advertisement

Key Points

  • CARE Track patients had significantly fewer end-of-life hospitalizations, with 48.3% of patients being hospitalized in the final 90 days of life, compared to 64% of the control group.
  • Additionally, the CARE Track patients received more hospice care than the control group (69.6% vs 47%), which resulted in fewer hospital deaths for the CARE Track group than the control group (8.4% vs 38.5%). This difference in end-of-life care resulted in a reduced mean total cost of $7,317 per patient in the last 90 days of life.
  • STAT RAD—a more rapid workflow for palliative radiation therapy for patients with bone metastases—helped patients report 80%–90% partial or complete pain relief by 3 months.

A collaborative, patient-reported outcome–based approach by palliative care and radiation oncology teams results in better outpatient symptom management and a decrease in end-of-life hospitalizations and costs for late-stage cancer patients, according to research presented by Read et al (Abstract LBA4) on October 18 at the American Society for Radiation Oncology’s (ASTRO’s) 57th Annual Meeting in San Antonio, Texas. The data also showed that through the implementation of rapid palliative radiotherapy that includes shorter, higher doses of radiation therapy, many patients experience pain relief within 1 week of treatment.

CARE Track

Starting in 2012, researchers at the University of Virginia Health System developed an integrated patient care program for advanced cancer patients that utilized information from patient-reported outcomes to improve patients’ health and quality of life and reduce costs of care. The program emphasized reducing hospitalizations and improving outpatient management of patients. The collection of patient-reported outcome assessments was initiated for all patients beginning in October 2013, following a pilot testing phase completed in February 2013.

A patient questionnaire that asked patients how they were doing emotionally and physically was incorporated into the facility’s electronic medical records system. A comprehensive assessment and rapid evaluation and treatment (CARE Track) palliative care team was alerted by the system to clinically significant reported changes in a patient’s status.

A total of 646 cancer patients were enrolled into the CARE Track program. End-of-life data for 368 CARE Track patients were compared to end-of-life data for 198 patients not enrolled in the CARE Track program. A total of 967 patient-reported outcome surveys were completed by the 368 CARE Track patients.

The CARE Track patients had significantly fewer end-of-life hospitalizations, with 48.3% of patients being hospitalized in the final 90 days of life, compared to 64% from the control group. Additionally, the CARE Track patients received more hospice care than the control group (69.6% vs 47%), which resulted in fewer hospital deaths for the CARE Track group than the control group (8.4% vs 38.5%). This difference in end-of-life care resulted in a reduced mean total cost of $7,317 per patient in the last 90 days of life.

STAT RAD

A multidisciplinary Supportive Care Tumor Board was also developed that met weekly to develop rapid and coordinated care plans for highly symptomatic patients. To respond more quickly to pain control, the team developed STAT RAD—a more rapid workflow for palliative radiation therapy for patients with bone metastases with the goal of turning a common 2- to 3-week treatment course into a 1-day treatment procedure with highly focused radiation treatment to reduce treatment-related toxicity.

The STAT RAD pilot clinical trial enrolled 28 patients. The patients each had between one and three painful bone metastases (37 target lesions) and received radiotherapy at 5 to 10 Gy per fraction, for between two and five fractions. An average of 21.6 Gy in 3.1 fractions was administered.

The pain response of patients in the STAT RAD program was assessed using the International Bone Metastasis Consensus Working Party, and patients’ quality of life was assessed using the Functional Assessment of Cancer Therapy - Bone Pain Scale.  Patients reported 80% to 90% partial or complete pain relief by 3 months; quality of life was significantly improved for patients for a time frame ranging from 1 week post STAT RT to 26 weeks post STAT RAD. 

A second clinical trial is still accruing patients and is exploring single-fraction STAT RAD with dose escalation from 8 Gy to 15 Gy so that the entire course of simulation, planning, quality assurance, and treatment can be completed in a single 3- to 4-hour patient-centric procedure.

“If we listen to our patients carefully, talk to them about their changing medical and emotional needs, and develop rapid and coordinated treatment plans, we can improve their quality of life and reduce their need for hospitalization for symptom management at the end of life,” said Paul W. Read, MD, PhD, Professor of Radiation Oncology at the University of Virginia Health System. “Integrating patient surveys to collect patient-reported outcomes directly into electronic medical records and incorporating them into routine clinical care can be done in most hospital systems,” he noted.

“The concept of tumor boards for multispecialty care planning of curative cancer patients is practiced throughout the country, and extending this concept to palliative care management is easy and straightforward,” Dr. Read continued. “Single-fraction radiation therapy for palliation of bone metastases for advanced cancer patients with short life expectancies is an accepted national care guideline and has been studied for decades in clinical trials. Therefore, these programs can all be adopted into clinical practice at most health systems with minimal cost, training, or education.”

The content in this post has not been reviewed by the American Society of Clinical Oncology, Inc. (ASCO®) and does not necessarily reflect the ideas and opinions of ASCO®.


Advertisement

Advertisement




Advertisement